Claims for Patent: 7,977,381

Summary for Patent: 7,977,381

Title:	Platinum complexes and methods for inhibiting tumor cell proliferation
Abstract:	The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.
Inventor(s):	Kay; Heidi (Wesley Chapel, FL), Palmer; Jay W. (Sun City Center, FL), Stanko; Joseph A. (Temple Terrace, FL), Sebti; Said M. (Tampa, FL)
Assignee:	University of South Florida (Tampa, FL)
Application Number:	11/703,497
Patent Claims:	1. A method for treating an oncological disorder in a patient, said method comprising administering an effective amount of a platinum complex to the patient, wherein said platinum complex has the structure: ##STR00070## ##STR00071## ##STR00072## ##STR00073## ##STR00074## ##STR00075## ##STR00076## ##STR00077## or a pharmaceutically acceptable salt of any of the foregoing; and wherein said oncological disorder is ovarian cancer, testicular cancer, bladder cancer, pancreatic cancer, or lung cancer. 2. The method according to claim 1, wherein the patient is a mammal. 3. The method according to claim 1, wherein the patient is a human, monkey, chimpanzee, ape, dog, cat, horse, cow, or pig. 4. The method according to claim 1, wherein said platinum complex is encapsulated in a liposome moiety or said platinum complex comprises a protein or nucleic acid that targets delivery of the platinum complex to a cell or said platinum complex comprises a moiety for transport across a cell membrane for intracellular delivery. 5. The method according to claim 1, wherein said platinum complex is administered to the patient via an oral, nasal, rectal, or parenteral route. 6. The method according to claim 1, wherein said platinum complex is administered in combination with other antitumor or anticancer substances or is administered in combination with radiation therapy or surgical treatment. 7. The method according to claim 6, wherein said substance is a mitotic inhibitor, an alkylating agent, an antimetabolite, a DNA intercalator, a topoisomerase inhibitor, an antiangiogenic agent, an antiestrogen, or an anti-cancer antibody. 8. The method according to claim 6, wherein said antitumor or anticancer substances, therapy, or treatment are provided at times different from administration of said platinum complex. 9. The method according to claim 1, wherein said platinum complex is provided in a pharmaceutically acceptable composition. 10. The method according to claim 1, wherein said method comprises identifying a patient who is or may be in need of treatment of said disorder. 11. A method for inhibiting the proliferation of a cancerous or tumorigenic cell, said method comprising contacting said cell with an effective amount of a platinum complex, wherein said platinum complex has the structure: ##STR00078## ##STR00079## ##STR00080## ##STR00081## ##STR00082## ##STR00083## ##STR00084## ##STR00085## or a pharmaceutically acceptable salt of any of the foregoing; and wherein said cell is an ovarian cell, a testicular cell, a bladder cell, a pancreatic cell, or a lung cell. 12. The method according to claim 11, wherein the cell is a mammalian cell. 13. The method according to claim 11, wherein the cell is from a human, monkey, chimpanzee, ape, dog, cat, horse, cow, or pig. 14. The method according to claim 11, wherein said platinum complex is encapsulated in a liposome moiety or said platinum complex comprises a protein or nucleic acid that targets delivery of the platinum complex to the cell. 15. The method according to claim 6, wherein said antitumor or anticancer substance is taxol, vinblastine, cyclophosamide, ifosfamide, 5-fluorouracil, hydroxyurea, adriamycin, bleomycin, etoposide, camptothecin, angiostatin, tamoxifen, imatinib, or trastuzumab. 16. The method according to claim 1, wherein said platinum complex is administered to said patient in a liposome, a slow release capsule, an implantable pump, or a biodegradable container. 17. The method according to claim 1, wherein said pharmaceutically acceptable salt is a sodium salt, potassium salt, calcium salt, ammonium salt, magnesium salt, hydrochloric salt, hydrobromic salt, nitric salt, phosphoric salt, carbonic salt, sulphuric salt, acetic salt, propionic salt, benzoic salt, succinic salt, fumaric salt, mandelic salt, oxalic salt, citric salt, tartaric salt, or maleic salt. 18. The method according to claim 11, wherein said pharmaceutically acceptable salt is a sodium salt, potassium salt, calcium salt, ammonium salt, magnesium salt, hydrochloric salt, hydrobromic salt, nitric salt, phosphoric salt, carbonic salt, sulphuric salt, acetic salt, propionic salt, benzoic salt, succinic salt, fumaric salt, mandelic salt, oxalic salt, citric salt, tartaric salt, or maleic salt. 19. The method according to claim 1, wherein the patient is a human. 20. The method according to claim 11, where said platinum complex is provided with a carrier.

Details for Patent 7,977,381

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2024-01-06
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2024-01-06
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2024-01-06